For the first quarter, Gilead earned $2.94 per share versus the consensus estimate of $2.32 per share.
Revenue came in at $7.59 billion for the period, also surpassing the consensus estimate of $6.92 billion.
The company also issued a higher guidance for the full year, compared to its previous forecast.
For 2015, the company now expects net product sales of between $28 billion to $29 billion, versus its prior forecast of $26 billion to $27 billion.
Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
The company's primary areas of focus include human immunodeficiency virus, liver diseases, oncology and respiratory conditions.
Gilead's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu.
Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook."
You can view the full analysis from the report here: GILD Ratings Report